Fig. 6
Loss of nf1 results in aberrant ERK/Akt/mTOR signaling in MYCN-driven neuroblastoma.
Immunohistochemical analysis of sagittal sections through tumors in the IRG of nf1a+/+;nf1b+/+;MYCN;GFP (A,D,G), nf1a+/-;nf1b+/+;MYCN;GFP (B,E,H) and nf1a-/-;nf1b+/+;MYCN;GFP (C,F,I) fish at the age of 6 weeks, using antibodies against phosphorylated ERK1/2 (pERK, A-C), phosphorylated AKT (pAKT, D-E) and phosphorylated S6 (pS6, G- I). Dotted lines indicate the tumor boundaries. The quantification of pERK-, pAKT- and pS6-positive tumor areas are shown in (J), with the red bars representing the median values. ns p>0.05, *p<0.05, **p<0.01 by two-tailed unpaired t-test.